TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Benzinga Logo Benzinga By Vandana Singh
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial

Gilead Sciences reported positive results from a Phase 3 clinical trial for a single-tablet HIV treatment combining bictegravir and lenacapavir, demonstrating non-inferiority to existing multi-tablet regimens with no significant safety concerns.

Insights
GOOGL   neutral

Mentioned as a partnership collaborator for commerce solutions


GILD   positive

Successful late-stage trial results for a novel single-tablet HIV treatment, meeting primary efficacy endpoints and showing promising safety profile, which could potentially expand treatment options for HIV patients